Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

is of safety and efficacy to be conducted based on predefined criteria. Kosan anticipates providing more information on the TIME-1 trial design upon initiation.

The TIME-2 clinical trial is being conducted at clinical sites primarily in the US and in Europe and is designed to enroll approximately 130 patients with relapsed-refractory multiple myeloma. The trial is designed to test three different doses of tanespimycin in combination with the approved dose and schedule of bortezomib (Velcade(R)) (1.3 mg/m2). The tanespimycin dose groups are 50 mg/m2, 175 mg/m2 and 340 mg/m2. Tanespimycin will be administered twice weekly as a one-hour intravenous infusion on a cycle of two weeks of treatment every three weeks (the same schedule as bortezomib). Patients eligible to participate in the TIME-2 trial must have been treated with and progressed following at least three prior treatments for multiple myeloma. Prior regimens must include bortezomib and lenalidomide (Revlimid(R)). The primary endpoint of the trial is the dose response based on objective response rate after 4 cycles of treatment. Secondary endpoints include a comparison of response rate between the three dose groups, progression-free survival, time to treatment failure and overall survival. Objective response rate in multiple myeloma is measured primarily by the patient's level of M protein.

About the Special Protocol Assessment

As stated in the Prescription Drug User Fee Act (PDUFA) and FDA's Guidance for Industry Special Protocol Assessment, "...having agreed to the design, execution, and analyses proposed in protocols reviewed under this process ... the Agency will not later alter its perspective on the issues of design, execution, or analyses unless public health concerns unrecognized at the time of protocol assessment under this process are evident. Thus, documented special protocol assessments should be considered binding on the review division and should not be changed at any time..." as
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. ... amended and increased its five-year revolving credit facility to ... an accordion feature that will allow the company to ... additional $30.0 million, subject to securing additional commitments from ... of the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... York (PRWEB) April 25, 2015 ... for vaginal mesh lawsuits filed against C.R. Bard, ... District Court, Southern District of West Virginia. According ... Scheduling Conference was convened that day, after certain ... Long Form Complaint. The Order directed that any ...
(Date:4/25/2015)... Henderson, NV (PRWEB) April 25, 2015 ... Program is still eliciting the excitement of the public ... well into the months of May and June. ... Wellness™ held their biannual tradition of "Special Prayers." More ... who had attended previous Special Prayers and have reported ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 Parker and Sons ... and cooling, has spiked in Arizona alongside the growing economy. ... additional forty employees for April to help account for the ... forty employees in April is something we are enthusiastic about. ... said Paul Kelly, president at Parker and Sons. , Indeed, ...
(Date:4/25/2015)... Dallas, TX/Minneapolis, MN (PRWEB) April 25, 2015 ... as the recipient of RFID Journal’s annual Best Implementation ... company that has demonstrated the best use of RFID ... operations. The winner is the company that best demonstrates ... The award was presented at RFID Journal Live! 2015 ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Constellations Recovery ... residence in Westchester County. Just 35 miles from New ... individuals back into everyday life while recovering from addiction. ... 7, 2015, will allow therapists, doctors and treatment centers ... learn more about the opportunities offered by Constellations Recovery., ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:Parker and Sons Plans to Expand in 2015 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3
... C did little to protect healthy men, either , , ... released Sunday cast doubt on the cardiac benefits of ... researchers found that low-dose aspirin did not reduce the ... diabetes. , Second, Harvard researchers concluded that neither vitamin ...
... Nov. 9, 2007 Mark Twain, a skeptic of the ... Man?" that humans do not command their minds or the ... a speaker identified as "old man" says in the essay. ... reflection or the need of it." , Twain,s views get ...
... interference when placed too closely to pacemakers, ICDs , , ... for your iPod into your coat pocket might not ... normal functioning of your implanted cardiac device. ... Association,s annual scientific sessions, in New Orleans, report that ...
... 9 The NHS Human,Services Foundation held its fifth ... the Hyatt Regency Penn,s Landing in Philadelphia. This event ... supports the mission,of NHS Human Services, one of the ... Every year the Foundation presents the Leading the ...
... Academy of Ophthalmology (Academy) and European Society of Ophthalmology ... meeting in the world, is in session November ... Center, Atlanta. Offerings include 277 continuing medical education ... transfer courses, and more than 100 hours of scientific ...
... Cataract Surgery Patients can Better Understand Their Condition at CataractSurgery.com ... ... Cataract surgery patients and their caregivers now have a new online ... . Cataracts affect nearly 20 million Americans age 60 ...
Cached Medicine News:Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 2Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 3Health News:Aspirin Doesn't Guard Diabetics Against Heart Disease 4Health News:Simple brain mechanisms explain arbitrary human visual decisions 2Health News:Simple brain mechanisms explain arbitrary human visual decisions 3Health News:MP3 Player Headphones May Throw Off Cardiac Devices 2Health News:MP3 Player Headphones May Throw Off Cardiac Devices 3Health News:Gala Raises Funds for NHS Human Services 2Health News:AAO-SOE Joint Meeting research highlights 2Health News:AAO-SOE Joint Meeting research highlights 3Health News:AAO-SOE Joint Meeting research highlights 4Health News:Alcon Sponsors Online Educational Initiative for Patients Considering Cataract Surgery 2
... patch, Duragen is a matrix for ... handles and conforms similar to normal ... matrix for dural closure. Remarkable onlay ... defects. Fully resorbed following complete tissue ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Elmed electrosurgical systems for major surgery....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Medicine Products: